|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0035245,
umls-concept:C0073992,
umls-concept:C0080103,
umls-concept:C0117996,
umls-concept:C0205178,
umls-concept:C0205191,
umls-concept:C0330390,
umls-concept:C0599756,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-3-26
|
|
pubmed:abstractText |
There is conflicting clinical evidence describing the response to long-acting beta-agonist (LABA) bronchodilators for patients with Arg16Gly beta(2)-adrenergic receptor (ADRB2 ) genotype differences. Furthermore, the role of inhaled corticosteroids (ICS) in modulating Arg16Gly clinical responses is not well understood. The objective of this study was to investigate the effects of Arg16Gly polymorphism on the 12 hour post-dose bronchodilator response to the LABA salmeterol (SAL) or SAL plus fluticasone propionate (FSC) on first administration and following 12 weeks of treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Albuterol,
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Glycine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2,
http://linkedlifedata.com/resource/pubmed/chemical/fluticasone,
http://linkedlifedata.com/resource/pubmed/chemical/salmeterol
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1011-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19275519-Adrenergic beta-Agonists,
pubmed-meshheading:19275519-Adult,
pubmed-meshheading:19275519-Albuterol,
pubmed-meshheading:19275519-Amino Acid Substitution,
pubmed-meshheading:19275519-Androstadienes,
pubmed-meshheading:19275519-Arginine,
pubmed-meshheading:19275519-Asthma,
pubmed-meshheading:19275519-Bronchodilator Agents,
pubmed-meshheading:19275519-DNA,
pubmed-meshheading:19275519-DNA Primers,
pubmed-meshheading:19275519-Female,
pubmed-meshheading:19275519-Genotype,
pubmed-meshheading:19275519-Glycine,
pubmed-meshheading:19275519-Humans,
pubmed-meshheading:19275519-Male,
pubmed-meshheading:19275519-Middle Aged,
pubmed-meshheading:19275519-Polymorphism, Genetic,
pubmed-meshheading:19275519-Receptors, Adrenergic, beta-2,
pubmed-meshheading:19275519-Respiratory Function Tests,
pubmed-meshheading:19275519-Retrospective Studies,
pubmed-meshheading:19275519-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.
|
|
pubmed:affiliation |
GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.
|
|
pubmed:publicationType |
Journal Article
|
